Cairo – Mubasher: Gilead Sciences signed a non-exclusive licensing agreement with Eva Pharma for manufacturing and selling remdesivir, a promising treatment for coronavirus (COVID-19), in 127 countries, including Egypt.
Under the deal, Eva Pharma, along with other companies based in India and Pakistan, “will have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly,” according to a recent statement.
“The licensees also set their own prices for the generic product they produce,” the statement showed.
The initial clinical trials have shown that remdesivir may improve recovery time for people with moderate to critical symptoms.
The licence is royalty-free until the the end of the public heath emergency, or another drug or vaccine is approved for treatment or prevention of the virus.
